Recombinant HIV type 1 (Clade-B) TAT Protein

Name: Recombinant HIV type 1 (Clade-B) TAT Protein
SKU: DAG1547
Rating: 5 (1 reviews)

HIV type 1 TAT, recombinant protein from E. coli

COA

SDS

Datasheet

Summary

Product Overview

HIV-1 TAT Recombinant- produced in E.coli is a single, non-glycosylated, polypeptide chain containing 86 amino acids encoded by two exons and having chain having a molecular mass of 14kDa.

Nature

Recombinant

Tag/Conjugate

Unconjugated

Purity

Greater than 90.0% as determined by HPLC analysis and SDS-PAGE.

Format

Sterile Filtered and lyophilized, though might appear as a solution as a result of the glycerol content.

Buffer

Lyophilized with 0.1% glycerol.

Preservative

None

Storage

2-8°C short term, -20°C long term

Introduction

The human immunodeficiency virus (HIV) is a lentivirus (slowly replicating retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells.

Antigen Description

Tat is an HIV gene.Tat stands for "Trans-Activator of Transcription". Tat consists of between 86 and 101 amino acids depending on the subtype.Also, in molecular biology, Tat is a protein which is encoded for by the Tat gene in HIV-1. Tat, is a regulatory protein that drastically enhances the efficiency of viral transcription.

Keywords

p14; Tat; Tat protein; Transactivating regulatory protein; HIV tat

Citations

Have you cited DAG1547 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome

VIROLOGY

Authors: Tripathi, Snehlata; Chaubey, Binay; Barton, Beverly E.; Pandey, Virendra N.

Abstract

We have shown that polyamide nucleic acids (PNAs) targeted to the PBS (PNA(PBS)) and A-loop (PNA(A-loop) ) sequences, when transfected into cells, inhibit HIV-1 replication by blocking the initiation of reverse transcription via destabilizing tRNA(3)(Lys) Primer from the viral genome. Here we demonstrate that both PNA(PBS) and PNA(A-loop) Conjugated with the membrane-transducing peptide (MTD) vectors penetratin and Tat are rapidly taken up by cells and inhibit HIV1 replication. Moreover, MTD peptide conjugates of PNA(PBS) and PNA-loop displayed potent virucidal activity against HIV-1. Brief exposure of HIV-1 virions to these conjugates rendered them noninfectious. The IC50 values for virucidal activity were in the range of similar to 50 nM; IC50 values for inhibition of HIV-1 replication/infection were 0.5 mu M-0.7 mu M. The virucidal property of these conjugates suggests that a cocktail of anti-HIV-1 PNA-MTD peptide conjugates targeting critical regions of the HIV-1 genome could serve as a prophylactic agent for inactivating HIV-1 virions after exposure to HIV-1. (C) 2007 Elsevier Inc. All rights reserved.

Transdermal absorption and stability enhancement of salmon calcitonin by Tat peptide

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Authors: Manosroi, Jiradej; Lohcharoenkal, Warangkana; Goetz, Friedrich; Werner, Rolf G.; Manosroi, Worapaka; Manosroi, Aranya

Abstract

Context: Highly organized structure of stratum corneum (SC) is the major barrier of the delivery of macromolecules such as proteins and peptides across the skin. Recently, cell penetrating peptides (CPPs) such as HIV1-trans-activating transcriptional (Tat) have been used to enhance the topical delivery of proteins and peptides. Objective: This study aimed to enhance the transdermal absorption and chemical stability of salmon calcitonin (sCT) by co-incubation with Tat. Materials and methods: Tat-sCT mixture at 1: 1 molar ratio was prepared. Transdermal absorption and chemical stability of the mixture was evaluated in comparing with free sCT. Results: Tat-sCT mixture gave higher cumulative amounts and fluxes of sCT than free sCT. The maximum percentage of sCT of 58.36 +/- 12.33% permeated into the receiving chamber was found in Tat-sCT mixture at 6 h which was 3.50 folds of free sCT. Tat-sCT mixture demonstrated better sCT stability than sCT solution after 1 month storage at 4 C, 25 degrees C and 45 degrees C. Discussion: The positively-charged arginine groups in Tat might be responsible for the binding of peptide complexes to negatively charged cell surfaces by electrostatic interactions and also the translocation of sCT through the excised skin. Conclusion: This study demonstrated the enhancements of transdermal absorption and stability of sCT by Tat peptide with potential for further application in transdermal delivery of other therapeutic peptides.